Jpmorgan Chase & CO Oramed Pharmaceuticals Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Oramed Pharmaceuticals Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 6,921 shares of ORMP stock, worth $16,541. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,921

Previous 11,210 38.26%

Holding current value

$16,541

Previous $32,000 46.88%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$2.07 - $2.83 $8,878 - $12,137	-4,289 Reduced 38.26%	6,921 $17,000
Q1 2024 May 10, 2024	SELL	$2.18 - $3.58 $38,272 - $62,850	-17,556 Reduced 61.03%	11,210 $32,000
Q4 2023 Feb 12, 2024	SELL	$1.71 - $2.57 $29,497 - $44,332	-17,250 Reduced 37.49%	28,766 $66,000
Q3 2023 Nov 14, 2023	SELL	$2.51 - $3.55 $19,665 - $27,814	-7,835 Reduced 14.55%	46,016 $120,000
Q2 2023 Aug 11, 2023	SELL	$2.12 - $4.47 $254,974 - $537,611	-120,271 Reduced 69.07%	53,851 $192,000
Q1 2023 May 11, 2023	SELL	$1.93 - $13.1 $444,855 - $3.02 Million	-230,495 Reduced 56.97%	174,122 $379,000
Q4 2022 Feb 13, 2023	BUY	$5.88 - $12.03 $705,682 - $1.44 Million	120,014 Added 42.17%	404,617 $4.87 Million
Q3 2022 Nov 14, 2022	SELL	$4.6 - $9.91 $238,951 - $514,784	-51,946 Reduced 15.43%	284,603 $1.84 Million
Q2 2022 Aug 11, 2022	BUY	$3.72 - $9.0 $1.19 Million - $2.87 Million	318,801 Added 1796.26%	336,549 $1.54 Million
Q1 2022 May 11, 2022	SELL	$8.19 - $13.89 $140,941 - $239,033	-17,209 Reduced 49.23%	17,748 $153,000
Q4 2021 Feb 10, 2022	BUY	$12.98 - $29.75 $308,262 - $706,532	23,749 Added 211.89%	34,957 $499,000
Q3 2021 Nov 12, 2021	BUY	$12.13 - $23.82 $135,953 - $266,974	11,208 New	11,208 $246,000

Others Institutions Holding ORMP

# of Institutions

Shares Held

6.37M

Call Options Held

Put Options Held

View Full List

About ORAMED PHARMACEUTICALS INC.

Ticker ORMP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,100
Market Cap $92.8M
Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...

More about ORMP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Oramed Pharmaceuticals Inc. Transaction History